Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Harvard Business School
McKinsey
AstraZeneca
Johnson and Johnson

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,232,572

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,232,572 protect, and when does it expire?

Patent 7,232,572 protects ORACEA and is included in one NDA.

This patent has nineteen patent family members in twelve countries.

Summary for Patent: 7,232,572
Title:Methods of treating rosacea
Abstract:A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.
Inventor(s): Ashley; Robert A. (Tucson, AZ)
Assignee: CollaGenex Pharmaceuticals, Inc. (Newtown, PA)
Application Number:11/061,866
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,232,572
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,232,572

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp ORACEA doxycycline CAPSULE;ORAL 050805-001 May 26, 2006 RX Yes Yes   Start Trial   Start Trial TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,232,572

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 330615   Start Trial
Australia 2002303250   Start Trial
Canada 2440472   Start Trial
Canada 2719162   Start Trial
Germany 60212613   Start Trial
Denmark 1383508   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Johnson and Johnson
Mallinckrodt
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.